Carregant...
How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors
Poly(ADP-ribose)polymerase (PARP) inhibitors are targeted therapy for cancers with homologous repair deficiency (HRD). They were first approved for ovarian cancer and have changed current treatment strategies. They have also demonstrated efficacy in HER2-negative metastatic breast cancer and advance...
Guardat en:
| Publicat a: | Ther Adv Med Oncol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7052467/ https://ncbi.nlm.nih.gov/pubmed/32165926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919897530 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|